Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Medical Center
mi
from
Vallejo, CA
A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Medical Center
mi
from
Vallejo, CA
Click here to add this to my saved trials
SGI-110 Plus Durvalumab/Tremelimumab in SCLC
A Phase I Study Evaluating the Safety and Efficacy of SGI-110 Followed by Combined Durvalumab Plus Tremelimumab in Subjects With Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
SGI-110 Plus Durvalumab/Tremelimumab in SCLC
A Phase I Study Evaluating the Safety and Efficacy of SGI-110 Followed by Combined Durvalumab Plus Tremelimumab in Subjects With Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
Kadlec Clinic Hematology and Oncology
mi
from
Kennewick, WA
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
Kadlec Clinic Hematology and Oncology
mi
from
Kennewick, WA
Click here to add this to my saved trials
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
University Cancer and Blood Center LLC
mi
from
Athens, GA
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
University Cancer and Blood Center LLC
mi
from
Athens, GA
Click here to add this to my saved trials
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
Illinois Cancer Care Jesse Brown VA
mi
from
Peoria, IL
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
Illinois Cancer Care Jesse Brown VA
mi
from
Peoria, IL
Click here to add this to my saved trials
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
University of Iowa Hospitals & Clinics Comprehensive Cancer Center
mi
from
Iowa City, IA
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
University of Iowa Hospitals & Clinics Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
Oncology Consultants Oncology Consultants, P.A.
mi
from
Houston, TX
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
Oncology Consultants Oncology Consultants, P.A.
mi
from
Houston, TX
Click here to add this to my saved trials
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
California Pacific Medical Center Drug Shipment (2)
mi
from
San Francisco, CA
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
California Pacific Medical Center Drug Shipment (2)
mi
from
San Francisco, CA
Click here to add this to my saved trials
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates of Treasure Coast
mi
from
Port Saint Lucie, FL
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates of Treasure Coast
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
Northwestern University Med School
mi
from
Chicago, IL
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
Northwestern University Med School
mi
from
Chicago, IL
Click here to add this to my saved trials
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
University of Illinois Cancer Center at Chicago SC
mi
from
Chicago, IL
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
University of Illinois Cancer Center at Chicago SC
mi
from
Chicago, IL
Click here to add this to my saved trials
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
Indiana University
mi
from
Indianapolis, IN
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
University of Kansas Clinical Research Center
mi
from
Fairway, KA
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
University of Kansas Clinical Research Center
mi
from
Fairway, KA
Click here to add this to my saved trials
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
Weinberg Cancer Institute at Franklin Square Hospital
mi
from
Baltimore, MD
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
Weinberg Cancer Institute at Franklin Square Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
Oncology Hematology West, PC dba Nebraska Cancer Specialists
mi
from
Omaha, NE
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
Oncology Hematology West, PC dba Nebraska Cancer Specialists
mi
from
Omaha, NE
Click here to add this to my saved trials
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers
mi
from
Las Vegas, NV
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers
mi
from
Las Vegas, NV
Click here to add this to my saved trials
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
Providence Regional Cancer System SC
mi
from
Lacey, WA
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
Providence Regional Cancer System SC
mi
from
Lacey, WA
Click here to add this to my saved trials
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
Billings Clinic Dept of Billings Clinic(2)
mi
from
Billings, MT
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
Billings Clinic Dept of Billings Clinic(2)
mi
from
Billings, MT
Click here to add this to my saved trials
Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy
A Phase II Study Evaluating the Efficacy of Iressa Plus Etoposide in Patients With Advanced Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy
A Phase II Study Evaluating the Efficacy of Iressa Plus Etoposide in Patients With Advanced Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2
Status: Enrolling
Updated:  12/31/1969
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2
Status: Enrolling
Updated: 12/31/1969
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2
Status: Enrolling
Updated:  12/31/1969
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2
Status: Enrolling
Updated: 12/31/1969
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Optimization of Remotely Delivered Physical Activity Intervention for Breast Cancer Survivors
Designing With Dissemination in Mind: Optimization of a mHealth Physical Activity Intervention for Breast Cancer Survivors
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Optimization of Remotely Delivered Physical Activity Intervention for Breast Cancer Survivors
Designing With Dissemination in Mind: Optimization of a mHealth Physical Activity Intervention for Breast Cancer Survivors
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Telephone-Based Mindfulness CBT for Patients in Community Settings With Advanced Cancer
Telephone-Based Mindfulness CBT for Patients in Community Settings With Advanced Cancer
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Telephone-Based Mindfulness CBT for Patients in Community Settings With Advanced Cancer
Telephone-Based Mindfulness CBT for Patients in Community Settings With Advanced Cancer
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Decision Impact Trial of the ExoDx Prostate (IntelliScore)
A Prospective, Randomized Blinded, Shared Decision Impact Trial of the ExoDx Prostate (IntelliScore), EPI Test, in Men Presenting for Initial Biopsy.
Status: Enrolling
Updated:  12/31/1969
Chesapeake Urology Research Associates
mi
from
Towson, MD
Decision Impact Trial of the ExoDx Prostate (IntelliScore)
A Prospective, Randomized Blinded, Shared Decision Impact Trial of the ExoDx Prostate (IntelliScore), EPI Test, in Men Presenting for Initial Biopsy.
Status: Enrolling
Updated: 12/31/1969
Chesapeake Urology Research Associates
mi
from
Towson, MD
Click here to add this to my saved trials
EndoRings Colonoscopy vs Standard Colonoscopy
NEXT Study - New Extra Detection Technology With EndoRings III
Status: Enrolling
Updated:  12/31/1969
Indiana University
mi
from
Indianapolis, IN
EndoRings Colonoscopy vs Standard Colonoscopy
NEXT Study - New Extra Detection Technology With EndoRings III
Status: Enrolling
Updated: 12/31/1969
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma
A Phase I Trial of Vaccination With Autologous, Lethally Irradiated Tumor Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Colony Stimulating Factor in Pediatric and Adult Patients
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Boston
mi
from
Boston, MA
Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma
A Phase I Trial of Vaccination With Autologous, Lethally Irradiated Tumor Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Colony Stimulating Factor in Pediatric and Adult Patients
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma
A Phase I Trial of Vaccination With Autologous, Lethally Irradiated Tumor Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Colony Stimulating Factor in Pediatric and Adult Patients
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma
A Phase I Trial of Vaccination With Autologous, Lethally Irradiated Tumor Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Colony Stimulating Factor in Pediatric and Adult Patients
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Genetic Risk: Whether, When, and How to Tell Adolescents
Genetic Risk: Whether, When, and How to Tell Adolescents
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins
mi
from
Baltimore, MD
Genetic Risk: Whether, When, and How to Tell Adolescents
Genetic Risk: Whether, When, and How to Tell Adolescents
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Using Virtual Reality (VR) Models for Preoperative Planning - UNC
Using Virtual Reality (VR) Models for Preoperative Planning - UNC
Status: Enrolling
Updated:  12/31/1969
UNC Hospital
mi
from
Chapel Hill, NC
Using Virtual Reality (VR) Models for Preoperative Planning - UNC
Using Virtual Reality (VR) Models for Preoperative Planning - UNC
Status: Enrolling
Updated: 12/31/1969
UNC Hospital
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma
A Phase I Clinical Trial of GM-CSF Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma
A Phase I Clinical Trial of GM-CSF Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Improving Communication Between Cancer Patients & Oncologists
Improving Communication Between Cancer Patients and Oncologists Using Patient Feedback on Actual Conversations and the ABIM Maintenance of Certification Program
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Improving Communication Between Cancer Patients & Oncologists
Improving Communication Between Cancer Patients and Oncologists Using Patient Feedback on Actual Conversations and the ABIM Maintenance of Certification Program
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
Phase I Dose Escalation Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham, Comprehensive Cancer Center
mi
from
Birmingham, AL
Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
Phase I Dose Escalation Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham, Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
A Phase 1b/2 Study of Hypofractionated Radiation and Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
A Phase 1b/2 Study of Hypofractionated Radiation and Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Neoadjuvant Treatment of Breast Cancer
Neoadjuvant Biweekly Doxorubicin and Cyclophosphamide With GMCSF Followed by Weekly Carboplatin/Nab-paclitaxel Plus or Minus Trastuzumab and Plus or Minus Bevacizumab in Treatment of Large or Inflammatory Breast Cancer-a Phase II Study
Status: Enrolling
Updated:  12/31/1969
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Neoadjuvant Treatment of Breast Cancer
Neoadjuvant Biweekly Doxorubicin and Cyclophosphamide With GMCSF Followed by Weekly Carboplatin/Nab-paclitaxel Plus or Minus Trastuzumab and Plus or Minus Bevacizumab in Treatment of Large or Inflammatory Breast Cancer-a Phase II Study
Status: Enrolling
Updated: 12/31/1969
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System
Harvest of Circulating Tumor Cells (CTCs) From Patients With Metastatic Breast Cancer (MBC) Using the Parsortix™ PC1 System
Status: Enrolling
Updated:  12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System
Harvest of Circulating Tumor Cells (CTCs) From Patients With Metastatic Breast Cancer (MBC) Using the Parsortix™ PC1 System
Status: Enrolling
Updated: 12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System
Harvest of Circulating Tumor Cells (CTCs) From Patients With Metastatic Breast Cancer (MBC) Using the Parsortix™ PC1 System
Status: Enrolling
Updated:  12/31/1969
University of Rochester Medical Center Wilmot Cancer Institute
mi
from
Rochester, NY
Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System
Harvest of Circulating Tumor Cells (CTCs) From Patients With Metastatic Breast Cancer (MBC) Using the Parsortix™ PC1 System
Status: Enrolling
Updated: 12/31/1969
University of Rochester Medical Center Wilmot Cancer Institute
mi
from
Rochester, NY
Click here to add this to my saved trials
Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System
Harvest of Circulating Tumor Cells (CTCs) From Patients With Metastatic Breast Cancer (MBC) Using the Parsortix™ PC1 System
Status: Enrolling
Updated:  12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System
Harvest of Circulating Tumor Cells (CTCs) From Patients With Metastatic Breast Cancer (MBC) Using the Parsortix™ PC1 System
Status: Enrolling
Updated: 12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System
Harvest of Circulating Tumor Cells (CTCs) From Patients With Metastatic Breast Cancer (MBC) Using the Parsortix™ PC1 System
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System
Harvest of Circulating Tumor Cells (CTCs) From Patients With Metastatic Breast Cancer (MBC) Using the Parsortix™ PC1 System
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
BrUOG-EG-203 Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer
BrUOG-EG-203 Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer BMS#CA225091
Status: Enrolling
Updated:  12/31/1969
Brown University Oncology Group
mi
from
Providence, RI
BrUOG-EG-203 Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer
BrUOG-EG-203 Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer BMS#CA225091
Status: Enrolling
Updated: 12/31/1969
Brown University Oncology Group
mi
from
Providence, RI
Click here to add this to my saved trials
Preventing Persistent Pain and Reducing Depressive and Anxious Symptoms Following Mastectomy and Lumpectomy
Preventing Persistent Pain and Reducing Depressive and Anxious Symptoms Following Mastectomy and Lumpectomy
Status: Enrolling
Updated:  12/31/1969
University of Iowa Hospital and Clinics
mi
from
Iowa City, IA
Preventing Persistent Pain and Reducing Depressive and Anxious Symptoms Following Mastectomy and Lumpectomy
Preventing Persistent Pain and Reducing Depressive and Anxious Symptoms Following Mastectomy and Lumpectomy
Status: Enrolling
Updated: 12/31/1969
University of Iowa Hospital and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)
Status: Enrolling
Updated:  12/31/1969
John Wayne Cancer Institute
mi
from
Santa Monica, CA
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)
Status: Enrolling
Updated: 12/31/1969
John Wayne Cancer Institute
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials